In the COMBI-MB trial, evaluating the clinical activity of the combination of dabrafenib and trametinib on brain metastases in BRAF-mutated melanoma patients, an intracranial response rate of 56% and a PFS at 6 and 12 months of 71 and 47%, respectively, was demonstrated in cohort B of asymptomatic patients with prior local therapy (46). The gene discussed is BRAF; the disease is melanoma.